

Daniel P Cahill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8403294/publications.pdf>

Version: 2024-02-01

181
papers

15,086
citations

53660

45
h-index

21474

114
g-index

185
all docs

185
docs citations

185
times ranked

21131
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Dâ€²â€²-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€²receive/B₀</sub>â€²shim array coils at 3â€²%T. NMR in Biomedicine, 2022, 35:1-6 e4621.		2
2	Implementation of <i>TERT</i> promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	8
3	Trabectedin for recurrent WHO grade 2 or 3 meningiomasâ€²paving the road for new opportunities. Neuro-Oncology, 2022, , .	0.6	0
4	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nature Communications, 2022, 13, 1325.	5.8	31
5	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in <i>BRAFV600E</i>-mutant High-grade Glioma. Clinical Cancer Research, 2022, 28, 2425-2439.	3.2	17
6	Enhancing demethylation-induced differentiation in IDH-mutant glioma. Neuro-Oncology, 2022, , .	0.6	0
7	In Vivo Absolute Metabolite Quantification Using a Multiplexed <scp>ERETICâ€²RX</scp> Array Coil for Wholeâ€²Brain <scp>MR</scp> Spectroscopic Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 121-133.	1.9	2
8	ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. Neuro-Oncology, 2022, 24, 888-900.	0.6	20
9	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 2022, 10, 996-1012.	1.6	18
10	Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study. Neurosurgery, 2021, 88, 63-73.	0.6	15
11	Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study. Neurosurgery, 2021, 88, E49-E59.	0.6	8
12	Sirtuin activation targets IDH-mutant tumors. Neuro-Oncology, 2021, 23, 53-62.	0.6	15
13	Extent of Resection of Glioblastoma. Neurosurgery Clinics of North America, 2021, 32, 23-29.	0.8	12
14	TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro-Oncology, 2021, 23, 76-87.	0.6	24
15	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. Neurologia Medico-Chirurgica, 2021, 61, 385-391.	1.0	4
16	Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathologica Communications, 2021, 9, 8.	2.4	12
17	Neurosurgical involvement in clinical trials for CNS tumors. Journal of Neuro-Oncology, 2021, 151, 367-373.	1.4	1
18	BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS. Neuro-Oncology Advances, 2021, 3, i5-i6.	0.4	0

#	ARTICLE	IF	CITATIONS
19	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	0.6	13
20	DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS. <i>Neuro-Oncology Advances</i> , 2021, 3, i6-i7.	0.4	0
21	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i12-i13.	0.4	1
22	Microscale Physiological Events on the Human Cortical Surface. <i>Cerebral Cortex</i> , 2021, 31, 3678-3700.	1.6	29
23	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	13.5	210
24	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	5.7	26
25	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3059-3059.	0.8	0
26	Evidence-based recommendations on categories for extent of resection in diffuse glioma. <i>European Journal of Cancer</i> , 2021, 149, 23-33.	1.3	97
27	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2000-2000.	0.8	18
28	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	15.2	67
29	Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy. <i>Clinical Neurophysiology</i> , 2021, 132, 1416-1432.	0.7	6
30	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , 2021, 4, e2120040.	2.8	27
31	Microscale dynamics of electrophysiological markers of epilepsy. <i>Clinical Neurophysiology</i> , 2021, 132, 2916-2931.	0.7	20
32	IMMU-08. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology Advances</i> , 2021, 3, iv6-iv6.	0.4	0
33	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	5.8	35
34	Commentary: The Glioma-Network Interface: A Review of the Relationship Between Glioma Molecular Subtype and Intratumoral Function. <i>Neurosurgery</i> , 2021, 88, E273-E274.	0.6	0
35	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi123.	0.6	0
36	EXTH-55. TARGETING RECURRENT IDH MUTANT GLIOMA WITH CDK4/6 INHIBITION. <i>Neuro-Oncology</i> , 2021, 23, vi175-vi175.	0.6	0

#	ARTICLE	IF	CITATIONS
37	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , 2021, 23, vi92-vi92.	0.6	0
38	CBIO-20. HIGH LEVELS OF TERT CONFER SENSITIVITY TO THE DNA HYPOMETHYLATING AGENT DECITABINE (DAC) IN GLIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi31-vi31.	0.6	0
39	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	0.6	0
40	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. <i>Neuro-Oncology</i> , 2021, 23, vi10-vi10.	0.6	0
41	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	0.6	0
42	CTIM-01. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , 2021, 23, vi48-vi49.	0.6	0
43	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49.	0.6	0
44	PATH-40. SPORADIC NF2 WILD-TYPE MULTIPLE MENINGIOMAS HARBOR DISTINCT DRIVER MUTATIONS. <i>Neuro-Oncology</i> , 2021, 23, vi124-vi124.	0.6	0
45	Neurologic complications of melanoma. <i>Cancer</i> , 2020, 126, 477-486.	2.0	0
46	A Multi-Institutional Analysis of Factors Influencing Surgical Outcomes for Patients with Newly Diagnosed Grade I Gliomas. <i>World Neurosurgery</i> , 2020, 135, e754-e764.	0.7	14
47	Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. <i>Clinical Cancer Research</i> , 2020, 26, 1690-1699.	3.2	76
48	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1α-mutated Human Gliomas. <i>Radiology</i> , 2020, 294, 589-597.	3.6	18
49	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. <i>Cancer Research</i> , 2020, 80, 5330-5343.	0.4	19
50	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , 2020, 8, 171.	2.4	58
51	An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7T. <i>Scientific Reports</i> , 2020, 10, 15029.	1.6	12
52	MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. <i>Neuro-Oncology</i> , 2020, 22, 1553-1554.	0.6	2
53	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. <i>Oncotmunology</i> , 2020, 9, 1806662.	2.1	26
54	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. <i>Acta Neuropathologica</i> , 2020, 140, 89-93.	3.9	32

#	ARTICLE	IF	CITATIONS
55	Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma. <i>Seminars in Radiation Oncology</i> , 2020, 30, 218-222.	1.0	1
56	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	15.2	83
57	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	9.4	177
58	Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD ⁺ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. <i>Cancer Discovery</i> , 2020, 10, 1672-1689.	7.7	30
59	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 378-387.	0.9	75
60	Real world use of a highly reliable imaging sign: T2-FLAIR mismatch for identification of IDH mutant astrocytomas. <i>Neuro-Oncology</i> , 2020, 22, 936-943.	0.6	77
61	Local Targeting of NAD ⁺ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. <i>Cancer Research</i> , 2020, 80, 5024-5034.	0.4	28
62	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2502-2502.	0.8	17
63	Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. <i>Journal of Neurosurgery</i> , 2020, , 1-10.	0.9	20
64	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2529-2529.	0.8	0
65	TAMI-30. LOCAL TARGETING OF NAD ⁺ SALVAGE PATHWAY ALTERS THE IMMUNE TUMOR MICROENVIRONMENT AND ENHANCES CHECKPOINT IMMUNOTHERAPY IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii219-ii219.	0.6	0
66	IMMU-01. SINGLE CELL SEQUENCING OF MELANOMA BRAIN METASTASES UNVEILS HETEROGENEITY OF THE TUMOR MICROENVIRONMENT IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , 2020, 22, ii104-ii104.	0.6	1
67	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, ii147-ii147.	0.6	0
68	EXTH-10. COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii88-ii89.	0.6	0
69	TMOD-13. RESEARCH RESOURCES FOR OLIGODENDROGLIOMA NOW AVAILABLE TO RESEARCH COMMUNITY. <i>Neuro-Oncology</i> , 2020, 22, ii230-ii230.	0.6	0
70	SURG-12. PREDICTORS OF SURVIVAL AND UTILITY OF INTRAOPERATIVE MRI FOR RESECTION OF GRADE II ASTROCYTOMAS AND OLIGODENDROGLIOMAS: A MULTICENTER ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii205-ii206.	0.6	0
71	TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE. <i>Neuro-Oncology</i> , 2020, 22, ii230-ii231.	0.6	1
72	CSIG-19. THE DEUBIQUITINASE BRCC3 LINKS ALT TELOMERES TO SUPPRESSION OF INNATE IMMUNITY IN IDH1-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii31-ii32.	0.6	0

#	ARTICLE	IF	CITATIONS
73	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. <i>Neuro-Oncology</i> , 2020, 22, ii13-ii13.	0.6	0
74	TAMI-36. CONNEXIN 43 BLOCKADE INHIBITS PROLIFERATION IN IDH1-MUTANT GLIOMA CELLS. <i>Neuro-Oncology</i> , 2020, 22, ii220-ii221.	0.6	0
75	TAMI-20. POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITION SEQUESTERS NAD ⁺ TO POTENTIATE THE METABOLIC LETHALITY OF ALKYLATING CHEMOTHERAPY IN IDH MUTANT TUMOR CELLS. <i>Neuro-Oncology</i> , 2020, 22, ii217-ii217.	0.6	0
76	Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients. <i>Neurosurgery</i> , 2019, 84, 519-528.	0.6	11
77	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. <i>Cancer</i> , 2019, 125, 2910-2914.	2.0	58
78	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	13.5	1,408
79	A Monoclonal Antibody Against α 21 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. <i>Targeted Oncology</i> , 2019, 14, 479-489.	1.7	12
80	Accelerated progression of IDH mutant glioma after first recurrence. <i>Neuro-Oncology</i> , 2019, 21, 669-677.	0.6	38
81	Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 562-567.	0.4	18
82	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. <i>Neuro-Oncology</i> , 2019, 21, 1401-1411.	0.6	70
83	Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 133-145.	1.8	65
84	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	3.2	26
85	Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping. <i>Clinical Neurophysiology</i> , 2019, 130, 1058-1065.	0.7	22
86	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	3.2	57
87	INN-27. THE IMPACT OF A DEDICATED MULTIDISCIPLINARY TUMOR BOARD ON CARE FOR PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology</i> , 2019, 21, vi135-vi136.	0.6	1
88	CBMT-19. THE ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM PROVIDES COLLATERAL SENSITIVITY TO LETHAL TELOMERIC FUSION INDUCED BY TRAPPING PARP INHIBITORS. <i>Neuro-Oncology</i> , 2019, 21, vi37-vi37.	0.6	1
89	CBMT-47. MODULATION OF NAD PATHWAYS AS A THERAPEUTIC STRATEGY FOR TARGETING IDH MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi43-vi43.	0.6	0
90	DRES-05. PREDICTORS OF SENSITIVITY TO COMBINED TEMOZOLOMIDE AND PARP INHIBITOR IN GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi72-vi72.	0.6	0

#	ARTICLE	IF	CITATIONS
91	RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi222-vi222.	0.6	0
92	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	1.9	36
93	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	2.5	77
94	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	0.6	1
95	NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi163-vi163.	0.6	0
96	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi59.	0.6	0
97	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase mutant Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 1261-1271.	3.2	50
98	Extent of Resection Versus Molecular Classification. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 95-101.	0.8	18
99	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. <i>Scientific Reports</i> , 2019, 9, 139.	1.6	9
100	Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. <i>Journal of Neuro-Oncology</i> , 2019, 141, 327-335.	1.4	72
101	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , 2019, 85, 204-210.	0.6	28
102	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. <i>Oncologist</i> , 2019, 24, 402-413.	1.9	3
103	The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13585-e13585.	0.8	1
104	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	5.8	106
105	Origin of Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 005-010.	0.5	52
106	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
107	CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION. <i>Neuro-Oncology</i> , 2018, 20, vi57-vi58.	0.6	1
108	EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING. <i>Neuro-Oncology</i> , 2018, 20, vi82-vi82.	0.6	0

#	ARTICLE	IF	CITATIONS
109	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi106-vi107.	0.6	0
110	MNGI-37. DMD GENOMIC DELETIONS CHARACTERIZE A SUBSET OF PROGRESSIVE/HIGHER-GRADE MENINGIOMAS WITH POOR OUTCOME. <i>Neuro-Oncology</i> , 2018, 20, vi157-vi157.	0.6	0
111	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , 2018, 20, vi56-vi57.	0.6	0
112	CSIG-34. PI3 KINASE PATHWAY ACTIVATION PROMOTES MALIGNANT PROGRESSION IN OLIGODENDROGLIAL TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi50-vi50.	0.6	0
113	Updates in prognostic markers for gliomas. <i>Neuro-Oncology</i> , 2018, 20, vii17-vii26.	0.6	78
114	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , 2018, 20, vi190-vi190.	0.6	0
115	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Nonâ€“Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 1598-1613.	7.7	71
116	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. <i>Acta Neuropathologica Communications</i> , 2018, 6, 106.	2.4	18
117	PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiencyâ€“Mediated Acquired Resistance to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2551-2563.	1.9	28
118	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. <i>Cell</i> , 2018, 175, 101-116.e25.	13.5	234
119	The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 591-603.	1.4	38
120	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. <i>PLoS ONE</i> , 2018, 13, e0202860.	1.1	28
121	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	3.3	40
122	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	15.2	359
123	TERT Alterations in Progressive Treatment-Resistant Meningiomas. <i>Neurosurgery</i> , 2018, 65, 66-68.	0.6	8
124	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	3.9	66
125	Phase II study of pembrolizumab in leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2007-2007.	0.8	19
126	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14041-e14041.	0.8	1

#	ARTICLE	IF	CITATIONS
127	TERT rearrangements to identify a subset of aggressive meningiomas.. Journal of Clinical Oncology, 2018, 36, e14028-e14028.	0.8	2
128	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	0.6	99
129	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. Neurosurgery, 2017, 80, 590-601.	0.6	34
130	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD+ Depletionâ€™ Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.4	74
131	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science, 2017, 355, .	6.0	743
132	Isocitrate dehydrogenaseâ€™ mutant glioma: Evolving clinical and therapeutic implications. Cancer, 2017, 123, 4535-4546.	2.0	103
133	Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell, 2017, 32, 411-426.e11.	7.7	161
134	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	2.3	49
135	Blockade of transforming growth factorâ€™ ² signaling enhances oncolytic herpes simplex virus efficacy in patientâ€™ derived recurrent glioblastoma models. International Journal of Cancer, 2017, 141, 2348-2358.	2.3	33
136	The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. Journal of Neuro-Oncology, 2017, 131, 565-574.	1.4	57
137	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas. Neurosurgery, 2017, 64, 134-138.	0.6	27
138	Reply to Freyschlag et al. Neuro-Oncology, 2017, 19, 598-599.	0.6	0
139	DRES-16. PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOMA MODELS. Neuro-Oncology, 2017, 19, vi67-vi67.	0.6	0
140	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. Neuro-Oncology, 2017, 19, vi75-vi75.	0.6	0
141	Clinically-actionable Mutations in Posterior Skull Base Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	1
142	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	0.8	89
143	Characterizing glioma microenvironment with ultra-high gradient diffusion MRI.. Journal of Clinical Oncology, 2017, 35, 2050-2050.	0.8	0
144	<i>TERT</i> promoter mutations in progressive treatment-resistant meningiomas.. Journal of Clinical Oncology, 2017, 35, 2047-2047.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 75-81.	1.8	17
146	Glioblastoma care in the elderly. Cancer, 2016, 122, 189-197.	2.0	53
147	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro-Oncology, 2016, 18, now100.	0.6	30
148	Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Neurosurgical Focus, 2016, 41, E2.	1.0	28
149	Case 38-2016. New England Journal of Medicine, 2016, 375, 2381-2389.	13.9	3
150	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research, 2016, 22, 4452-4465.	3.2	112
151	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research, 2016, 76, 6495-6506.	0.4	105
152	Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro-Oncology, 2016, 18, 1656-1663.	0.6	110
153	Single-cell RNA-seq supports a developmental hierarchy in human oligodendrogloma. Nature, 2016, 539, 309-313.	13.7	875
154	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. Journal of Clinical Neuroscience, 2016, 31, 99-105.	0.8	8
155	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro-Oncology, 2016, 18, 1278-1287.	0.6	25
156	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	3.0	182
157	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research, 2016, 22, 1632-1641.	3.2	127
158	ATPS-852-HYDROXYGLUTARATE DEPLETION IS NOT SUFFICIENT TO INHIBIT GROWTH OF SEVERAL PROGRESSIVE IDH1 MUTANT SOLID CANCER TYPES. Neuro-Oncology, 2015, 17, v37.2-v37.	0.6	2
159	MPTH-17CLINICAL AND MOLECULAR CHARACTERIZATION OF LONG-TERM GLIOBLASTOMA SURVIVORS. Neuro-Oncology, 2015, 17, v141.4-v142.	0.6	0
160	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. Neuro-Oncology, 2015, 17, v45.4-v45.	0.6	0
161	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	7.7	327
162	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathologica, 2015, 129, 585-596.	3.9	272

#	ARTICLE	IF	CITATIONS
163	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
164	The role of biopsy in the management of patients with presumed diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 481-501.	1.4	30
165	The role of neuropathology in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 531-549.	1.4	120
166	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	3.4	68
167	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. <i>CNS Oncology</i> , 2015, 4, 287-294.	1.2	48
168	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014, 16, 81-91.	0.6	370
169	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909.	3.2	146
170	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. <i>Journal of Neuro-Oncology</i> , 2014, 118, 405-412.	1.4	28
171	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. <i>Science</i> , 2014, 344, 1396-1401.	6.0	3,648
172	Targetable signaling pathway mutations and progression of <i>IDH</i>-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2061-2061.	0.8	0
173	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13022-e13022.	0.8	0
174	Mesenchymal Differentiation Mediated by NF- κ B Promotes Radiation Resistance in Glioblastoma. <i>Cancer Cell</i> , 2013, 24, 331-346.	7.7	856
175	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2029-2029.	0.8	7
176	IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2019-2019.	0.8	4
177	Case 10-2010. <i>New England Journal of Medicine</i> , 2010, 362, 1326-1333.	13.9	10
178	Mismatch repair defects underlying temozolomide chemoresistance in recurrent glioblastomas. <i>FASEB Journal</i> , 2008, 22, 172.2.	0.2	0
179	MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. <i>Clinical Neurosurgery</i> , 2008, 55, 165-71.	0.2	22
180	A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy. <i>Cancer Research</i> , 2006, 66, 3987-3991.	0.4	383

#	ARTICLE	IF	CITATIONS
181	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.4	2